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Abstract 
 
Background 
Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide 
range of individuals, but there is uncertainty about its efficacy and safety among older people.  
Methods 
Randomised trials of statin therapy were eligible if they aimed to recruit at least 1000 participants 
with scheduled treatment duration of at least 2 years. Individual participant data from 22 trials 
(n=134,537) and detailed summary data from one trial (n=12,705) of statin therapy versus control, 
plus individual participant data from 5 trials of more-intensive versus less-intensive statin therapy 
(n=39,612), were analysed. Participants were subdivided into age groups: ≤55 years; >55≤60 years; 
>60≤65 years; >65≤70 years; >70≤75 years; and >75 years. Effects on major vascular events (ie, 
major coronary events, strokes and coronary revascularisations), cause-specific mortality and cancer 
incidence were estimated as the rate ratio (RR) per 1.0 mmol/L (39mg/dL) LDL cholesterol reduction. 
Findings 
Among 186,854 participants in 28 trials, 14,483 (8%) were aged above 75 years at randomisation. 
Median follow-up duration was 4.9 years. Overall, statin/more therapy produced a proportional 
reduction in major vascular events of 21% (RR 0.79; 95% CI 0.77-0.81) per 1.0 mmol/L reduction in 
LDL cholesterol. Although the proportional reductions in major vascular events appeared to diminish 
slightly with age, the trend was not significant (trend p=0.06) and there was significant benefit in all 
age groups. With increasing age, there was a trend towards smaller risk reductions in major coronary 
events (trend p=0.009), but not in coronary revascularisation procedures (trend p=0.6) or stroke 
(trend p=0.7). After exclusion of 4 trials which enrolled only patients with heart failure or undergoing 
renal dialysis (among whom statin therapy has not been shown to be effective), the trend persisted 
for major coronary events (trend p=0.01), but remained non-significant for major vascular events 
(trend p=0.3). The proportional reduction in major vascular events was similar, irrespective of age, 
among patients with pre-existing vascular disease (trend p=0.2), but appeared smaller among older 
individuals not known to have vascular disease (trend p=0.05). There was a trend (p=0.004) towards 
smaller proportional reductions in vascular mortality with older age, but this did not persist after 
exclusion of the heart failure or dialysis trials (trend p=0.2). Statin therapy had no effect at any age 
on non-vascular mortality, cancer death or cancer incidence. 
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Interpretation 
Statin therapy produces significant reductions in major vascular events irrespective of age, but there 
is less direct evidence of benefit among patients aged over 75 who do not already have evidence of 
occlusive vascular disease; this limitation is now being addressed by further trials. 
Funding 
Australian National Health and Medical Research Council; UK Medical Research Council, British Heart 
Foundation. 
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Introduction 
 
Meta-analyses of individual participant data from 27 randomised trials in the Cholesterol Treatment 
Trialists’ (CTT) Collaboration database indicate that each 1.0 mmol/L reduction in LDL cholesterol 
with statin therapy reduces the risk of major vascular events by about one fifth, with similar 
proportional risk reductions among men and women,1 a1nd across different levels of absolute risk.2 
However, even among patients with established cardiovascular disease, utilisation rates of statin 
therapy have been shown to decline with increasing age, and are significantly lower in people aged 
over 75 years, reflecting differences in both prescribing and compliance.3,4 This trend is even more 
prominent among older patients who do not have evidence of occlusive vascular disease.5 One 
explanation may relate to uncertainty about applying the evidence for statin efficacy and safety from 
randomised trials to an elderly population, given that a relatively small number of people aged over 
75 were enrolled in such trials, and many elderly people have non-cardiovascular comorbidities.6-10 
The CTT collaboration has age-specific data on vascular events, cause-specific mortality and cancer 
from 28 randomised controlled trials of statin therapy among a total of nearly 187,000 participants, 
of whom about 14,500 were aged over 75 at baseline. Consequently, it is uniquely placed to help 
address uncertainties about the effects of statin treatment among older individuals.  
Methods 
 
Study Design 
Methods were pre-specified in a CTT collaboration protocol published prior to the reporting of any 
individual trial results.11 Randomised trials were eligible for inclusion if: (i) the main effect of at least 
one of the trial interventions was to lower LDL cholesterol; (ii) the trial was unconfounded with 
respect to this intervention; and (iii) the trial aimed to recruit 1000 or more participants with 
scheduled treatment duration of at least 2 years.11 As for all CTT analyses,1,2,11-16 the risk of bias was 
low owing to: pre-specified study methods; the ability to adjust for heterogeneity by weighting rate 
ratios according to trial-level absolute differences in LDL cholesterol; and the low probability of 
publication bias due to a prospective design with pre-specified study eligibility. Pre-specified 
outcomes included major coronary events (defined as non-fatal myocardial infarction (MI) or 
coronary death), coronary revascularisation (angioplasty or bypass grafting), stroke (subdivided by 
type), site-specific cancers and cause-specific mortality. Subsequently, major vascular events were 
defined as the composite of major coronary events, coronary revascularisation and stroke. Pre-
specified sub-group analyses included comparisons of the effects of statin therapy among people 
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aged ≤65 and >65 years at randomisation (along with several other subgroupings, including by 
history of vascular disease).11 11For the present analyses, we compared effects between six age 
groups (≤55, >55 to ≤60, >60 to ≤65, >65 to ≤70, >70 to ≤75 and >75 years) and, where statistical 
power was limited, between two retrospectively-defined groups (≤75 and >75 years). Due to a 
disproportionate representation of older people (particularly aged >75 years) in trials conducted 
exclusively among people with heart failure17,18 or receiving renal dialysis,19,20 for whom statin 
therapy shows little or no benefit, we also examined the effects after excluding these trials.   
 
Statistical Analysis 
The meta-analysis was conducted according to the intention-to-treat principle, using the same 
methods described previously.11,12,14 Results are presented as rate ratios per 1.0 mmol/L reduction in 
LDL cholesterol. 1,2,12-16Proportional risk reductions in different age subgroups were compared using 
standard χ2 tests for heterogeneity when there were two groups, or trend when there were more 
than two groups. To allow for multiple subdivisions of the data into subgroups, only summary rate 
ratios are presented with 95% CIs; all other rate ratios are presented with 99% CIs. All analyses were 
conducted using SAS software (version 9.3; SAS Institute Inc., Cary, NC, USA) and R version 3.2.5. 
 
Role of the funding source 
No funding source had any role in study design, data collection, data analysis, data interpretation or 
writing of this manuscript. The writing committee had full access to all the data in the study and take 
final responsibility for its content.  
Results 
 
Individual participant data were provided by investigators or sponsors for 27 trials of statin therapy, 
and one further trial21 provided detailed summary data, permitting meta-analyses of all 28 trials. 
Twenty three trials investigated the effects of statin therapy vs. control (147,242 participants; 
median follow-up 4.8 years) and five trials compared more intensive versus less intensive statin 
therapy (39,612 participants; median follow-up 5.1 years).1 Data were not available for four eligible 
trials (9,264 participants), all of which exclusively enrolled people with known vascular disease.22-25 
The median follow-up duration was 4.9 years, ranging from 2.0 years to 7.0 years. Of the 186,854 
participants, 39,242 (21%) were aged ≤55, 31,434 (17%) were aged >55 to ≤60, 37,764 (20%) were 
aged >60 to ≤65, 36,567 (20%) were aged >65 to ≤70, 27,314 (15%) were aged >70 to ≤75 and 
14,483 (8%) were aged>75 years (webtable 1; age was unrecorded for 50 participants).  
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There were significant differences in each of the measured baseline characteristics across the six age 
groups (p<0.001 for all comparisons; webtable 2). In particular, older participants were more likely 
to be female and to have heart failure or hypertension, and less likely to be current smokers. 
Patients included in heart failure trials comprised 20% of those aged >75 years compared to 4% of 
those aged ≤75 years; and patients in renal dialysis trials comprised 4% of patients aged >75 years 
compared to 2% of those aged ≤75 years (Table 1). There was a trend towards lower baseline LDL 
cholesterol concentrations with increasing age in the statin vs control trials and, to a lesser extent, in 
the more vs less statin trials.  Mean LDL-cholesterol differences between treatment arms at one year 
(overall difference 1.08 mmol/L) were slightly smaller among older participants (webtable 3).   
  
Among all 28 trials, statin/more therapy compared to control/less therapy produced a 21% (RR 0.79; 
95% CI 0.77-0.81) proportional reduction in the risk of a first major vascular event per 1.0 mmol/L 
reduction in LDL cholesterol. There were independently significant risk reductions in each of the age 
groups considered, including among patients aged over 75 at the start of treatment. Although the 
proportional reductions in major vascular events appeared to diminish slightly with increasing age, 
the trend was not statistically significant (trend p=0.06; figure 1(a)). It has previously been shown 
that statin therapy does not reduce the rate of major vascular events among patients with moderate 
or severe heart failure or who are undergoing dialysis for renal failure16-19,26 (heterogeneity 
p<0.0001; figure 2). Disproportionately more patients with heart failure or dialysis were represented 
from these trials in the older age groups, which could confound comparisons between the effects of 
statin therapy by age. In exploratory analyses, after exclusion of the 13,613 (7%) patients from the 
four trials restricted to heart failure or dialysis patients,17-19,26 the suggestion of a trend towards 
smaller proportional reductions in major vascular events with older individuals was diminished 
(trend p=0.3; figure 1(b)). These patterns were unchanged after adjustment for gender, diabetes, 
hypertension, smoking, prior CVD status, BMI and renal function (adjusted p for trend = 0.06 in 27 
trials with individual participant data; p=0.4 after excluding four trials that exclusively included 
participants with heart failure or on dialysis).  
 
Overall, statin/more therapy yielded a 24% (RR 0.76; 95% CI 0.73-0.79) proportional reduction in 
major coronary events per 1.0 mmol/L reduction in LDL cholesterol. There was a statistically 
significant trend towards smaller proportional reductions in major coronary events with increasing 
age (trend p=0.009; figure 3), which remained significant after excluding the heart failure and 
dialysis trials (trend p=0.01; webfigure 1). As for the analyses of major vascular events, these 
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patterns were unchanged after adjustment for gender, diabetes, hypertension, smoking, prior CVD 
status, BMI and renal function (adjusted p for trend = 0.008 in 27 trials with individual participant 
data; p=0.012 after excluding four trials that exclusively included participants with heart failure or on 
dialysis). Even among patients aged over 75, however, there was still a significant reduction in major 
coronary events. When comparisons were made between patients aged ≤75 or >75 years, there 
were no significant differences between the proportional effects on major coronary events, or on 
nonfatal myocardial infarctions and coronary deaths considered separately (with or without 
exclusion of the heart failure or dialysis trials; webfigure 2).  
 
Overall, there was a 25% (RR 0.75; 95% CI 0.73-0.78) proportional reduction in the risks of coronary 
revascularisation procedures with statin/more therapy per 1.0 mmol/L lower LDL cholesterol, which 
did not differ significantly across age categories (trend p=0.6), although there was no apparent effect 
on the relatively small number of procedures performed among patients aged >75 years (figure 3 
and webfigure 1). Similarly, the proportional reductions in stroke of any type (RR 0.84; 95% CI 0.80-
0.89) did not differ significantly by age group (trend p=0.7; figure 3).  
 
Among participants with known vascular disease at study entry, the proportional reductions in major 
vascular events were similar irrespective of age, regardless of whether heart failure and dialysis trials 
were included or excluded (trend p=0.2 and 0.9 respectively; figure 4 and webfigure 3). However, 
among participants with no history of vascular disease, there was a weakly significant trend towards 
smaller proportional risk reductions with increasing age (trend p=0.05; figure 4) that persisted after 
excluding the heart failure and dialysis trials (trend p=0.03; webfigure 3).  
 
Overall, there was a 12% (RR 0.88; 95% CI 0.85-0.91) proportional reduction in vascular mortality per 
1.0 mmol/L reduction in LDL cholesterol, with a trend towards smaller proportional reductions with 
older age (trend p=0.004; Figure 5(a)). However, 53% (n=1014) of the vascular deaths among people 
aged >75 occurred in the four heart failure or dialysis trials. After exclusion of those trials, there was 
no apparent trend towards smaller proportional reductions in vascular mortality with older age 
(p=0.2, figure 5(b)). There was no effect of statin therapy on all non-vascular causes of death (RR 
0.96; 95% CI 0.92-1.01) irrespective of age group (trend p=0.7; webfigure 4). Nor were there any 
adverse effects on deaths due to cancer, or on the larger numbers of incident cancer cases, by age 
(webfigure 5). Consequently, when the beneficial effect on vascular mortality and the lack of effect 
on non-vascular mortality was combined, there was a significant reduction in all-cause mortality (RR 
0.91; 95% CI 0.88-0.93). As for vascular mortality, there was a trend towards smaller proportional 
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reductions in all-cause mortality with increasing age (trend p=0.04, webfigure 6(a)), but this did not 
persist after excluding the heart failure and dialysis trials (trend p=0.1, webfigure 6(b)).  
Discussion 
 
Individual randomised trials of statin therapy have previously reported significant cardiovascular risk 
reductions among participants aged >65-70 years at the time of randomisation (who were therefore 
aged >70-75 years at the end of an average of five years of scheduled treatment).27-31 Meta-analyses 
of the results among older people have consistently reported evidence for beneficial effects in 
secondary prevention, but the evidence has been less clear in primary prevention.32-35 The 
availability of individual participant data in the CTT Collaboration database 21has permitted more 
detailed assessment of the effects of statin therapy at different ages.  
 
In this meta-analysis of data from 28 trials among nearly 187,000 people (with about 14,500 aged 
over 75 years at randomisation), there was a tendency towards slightly smaller proportional risk 
reductions in major vascular events (trend p=0.06) and vascular deaths (p=0.003) with increasing 
age. The exclusion criteria for 24 of these trials incorporated at least one of: a history of heart 
failure, poor ejection fraction, poor prognosis (other than from atherosclerotic disease) or the 
requirement for renal dialysis. However, two of the trials were conducted specifically in patients 
with moderate to severe (New York Heart Association (NYHA) Class II-IV) heart failure17,18 and two in 
patients with end-stage renal disease requiring dialysis.19,26 Statin therapy has not been shown to 
reduce the risk of major vascular events or vascular deaths in either of these patient populations,16-
19,26 and consequently is not recommended for such patients in the absence of other 
indications.10,36,37 We therefore conducted exploratory analyses that excluded these 4 trials17-19,26 in 
order to assess their contribution to the observed trends towards smaller relative reductions with 
increasing age. These analyses showed that, among people without heart or renal failure, there was 
little evidence of any diminution of the beneficial effect on major vascular events or on vascular 
deaths with increasing age (trend p=0.3 and 0.2 respectively).  
 
The proportional reductions in major vascular events also appeared to be similar irrespective of age 
among patients with a history of vascular disease (ie, secondary prevention), but there was a trend 
towards smaller proportional risk reductions in those with no known vascular disease (ie, primary 
prevention), with no independently significant reductions observed among the those >70 to ≤75 or 
>75 years of age. Only about one fifth of the major vascular events contributing to these analyses 
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occurred among individuals without a history of vascular disease, and this relative paucity of 
evidence has led to further primary prevention trials being conducted, particularly among older 
individuals. For example, the STAREE trial aims to assess the effects of atorvastatin 40mg daily in 
18,000 primary prevention patients aged ≥70 years at the time of recruitment.38  
 
There was a trend towards smaller proportional reductions in major coronary events (p=0.01) with 
increasing age, although there was still a significant reduction among the patients aged over 75 
years at randomisation. The reasons for this trend are unclear. Age related factors - such as altered 
pharmacokinetics and pharmacodynamics, and a higher risk of drug interactions in the setting of 
polypharmacy39 – would be expected to influence absolute LDL cholesterol reductions from therapy, 
but these did not differ materially by age. The trend may reflect a reduced capacity for statins to 
impact on advanced atherosclerotic plaques, greater diagnostic uncertainty at older ages (eg, 
difficulty separating myocardial infarctions due to unstable atherosclerosis from supply-demand 
imbalances that occur with other illnesses), and poorer long-term adherence with the assigned study 
treatment among older people (since our weighted analyses are based on one year LDL cholesterol 
differences). There were no trends towards smaller proportional reductions in coronary 
revascularisation procedures or strokes with increasing age, but too few such events occurred 
among patients aged over 75 to assess the effects on these outcomes directly. Statin therapy 
definitely decreases the risk of ischaemic stroke and any stroke overall, but may increase the risk of 
haemorrhagic stroke.14 Individual participant data were not available from one eligible trial22 in 
which a large number of strokes (especially haemorrhagic) occurred, and it is not currently possible 
to comment reliably on the relevance of age to the effects of statin therapy on stroke subtypes.  
 
There is limited information on the effects of statins on mortality in people at low risk of vascular 
disease, and very large trials (eg, the ongoing STAREE trial38) would be needed to provide direct 
evidence of a mortality reduction among older people in primary prevention. However, our overall 
analyses in a combined primary and secondary prevention population indicate that the proportional 
reductions in vascular mortality are similar irrespective of age. We have previously shown that statin 
therapy does not increase the incidence of cancer15 (as had been suggested8) or of non-vascular 
causes of death.14  Consequently, given the similar proportional reductions in vascular mortality in 
both primary and secondary prevention settings, and the lack of effect of statin therapy on non-
vascular mortality, reductions in total mortality would be expected in both clinical settings.  
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Statins have been estimated to increase the risk of myopathy (defined as muscle pain or weakness 
combined with large increases in blood concentrations of creatine kinase) typically by 1 case per 
10,000 statin-treated patients per year,9 but this risk can be increased by drug interactions and 
major comorbidities that are more common in older people.40 A meta-analysis of published data for 
participants aged ≥65 years at randomisation in statin trials reported no increased risks of less 
severe muscle-related adverse events.41 Currently the CTT is undertaking a pre-specified analysis of 
reported adverse events in statin trials from original trial records,42 including examining whether age 
directly influences the small increase in risk of diabetes,43,44 and whether statins adversely influence 
cognition (noting that no excess risks have been identified in any large randomised trials30,31,45,46) 
 
The selection criteria used among the 28 trials contributing to this meta-analysis, as well as 
differences in when they were conducted, mean that the absolute risks of major vascular events and 
mortality in our overall study population are not likely to be representative of any contemporary 
population. For that reason, we have not produced estimates of the absolute effects of statin 
therapy directly from the event rates observed in these trials. By contrast, the proportional effects 
observed in the meta-analysis are likely to be widely generalizable. Consequently, given that the 
proportional reductions in major vascular events appeared to diminish only slightly (if at all) with 
increasing age, while untreated absolute risks of major vascular events in the general population 
increase exponentially with age, the absolute benefits of a given absolute reduction in LDL 
cholesterol with statin therapy would be expected to be substantially greater among older 
individuals. For example, in the primary prevention setting, two individuals aged 63 or 78 years with 
otherwise identical risk factors might be expected to have major vascular event rates of 2.5% versus 
4.0% per annum respectively. Reducing those risks by one-fifth with a 1.0 mmol/L LDL cholesterol 
reduction would prevent first major vascular events from occurring each year in 50 and 80 
individuals respectively per 10,000 treated.  
 
In conclusion, statin therapy produces significant reductions in major vascular events irrespective of 
age. There is less definitive direct evidence of benefit in the primary prevention setting among 
patients aged over 75, but the totality of evidence supports the use of statin therapy in older people 
considered to be at a sufficiently high risk of having occlusive vascular events.  
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Figures 
 
Figure 1: Effects on MAJOR VASCULAR EVENTS per mmol/L reduction in LDL cholesterol, by age at 
randomisation 
Figure 2: Effects on MAJOR VASCULAR EVENTS per mmol/L reduction in LDL cholesterol, subdivided 
by age at randomisation and particular trial populations 
Figure 3: Effects on components of MAJOR VASCULAR EVENTS per mmol/L reduction in LDL 
cholesterol in all studies, by age at randomisation 
Figure 4: Effects on MAJOR VASCULAR EVENTS per mmol/L reduction in LDL cholesterol, subdivided 
by age at randomisation and by prior vascular disease 
Figure 5: Effects on VASCULAR DEATH per mmol/L reduction in LDL cholesterol, subdivided by age at 
randomisation 
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Tables and Figures
 Table 1: Baseline characteristics of participants in all studies  
 Age at randomisation, N(%)* 
 
≤75 >75 
Number of people 172,321 14,483 
Age (years) 61.5 (8.3) 78.8 (3.0) 
Male 125,783 (73%) 8,476 (58%) 
History of vascular disease 96,088 (56%) 8,034 (55%) 
     History of myocardial infarction 59,654 (35%) 4,210 (29%) 
History of other symptomatic coronary 
heart disease 
61,767 (35%) 4,448 (31%) 
History of heart failure  
   (NYHA class II-IV)† 
6,692 (4%) 2,893 (20%) 
On dialysis‡ 3,546 (2%) 482 (4%) 
History of diabetes 31,919 (19%) 2,499 (17%) 
Current smokers 35,701 (21%) 1,485 (10%) 
Treated hypertension 82,213 (49%) 8,698 (60%) 
Systolic blood pressure (mmHg) 138.1 (20.9) 143.4 (23.0) 
Diastolic blood pressure (mmHg) 81.2 (11.3) 78.9 (11.6) 
Body mass index (kg/m²) 27.1 (24.6-30.1) 26.3 (23.8-29.1) 
Total-cholesterol (mmol/L) 5.4 (1.1) 5.1 (1.1) 
LDL-cholesterol (mmol/L) 3.4 (1.0) 3.2 (1.0) 
HDL-cholesterol (mmol/L) 1.2 (0.4) 1.3 (0.5) 
Triglycerides (mmol/L) 1.6 (1.2-2.2) 1.4 (1.0-1.9) 
Creatinine (µmol/L)§ 94 (80-106) 99 (88-117) 
Data presented as number of participants (%), mean (SD) or median (IQR). HOPE-3 participant data for body mass 
index (mean (SD) 27.21 (4.77) among ≤75 and 26.14 (4.78) among >75 year old participants), triglycerides (149.02 
(94.14) and 140.07 (78.14), respectively) and creatinine (0.89 (0.21)); and 0.93 (0.23), respectively) not 
included.*Excludes 50 participants with missing age (49 from MEGA and 1 from A to Z). †All participants from GISSI-
HF and CORONA trials only. ‡All participants from 4D and AURORA trials. §Excludes participants on dialysis at 
randomisation (ie, participants from 4D and AURORA). 
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Figure 1: Effects on MAJOR VASCULAR EVENTS per mmol/L reduction in LDL cholesterol, by age
at randomisation
a) All studies
Events (% p.a.)
χ1
2
=3.56
(p=0.06)
 ≤ 55 years
 2217 (2.7)  2778 (3.4) 0.75 (0.70 − 0.81)
 >55, ≤ 60 years
 1741 (2.6)  2107 (3.2) 0.80 (0.74 − 0.87)
 >60, ≤ 65 years
 2238 (2.8)  2723 (3.5) 0.80 (0.74 − 0.86)
 >65, ≤ 70 years
 2263 (3.0)  2867 (3.9) 0.76 (0.71 − 0.82)
 >70, ≤ 75 years
 1993 (3.8)  2339 (4.5) 0.81 (0.74 − 0.88)
 >75 years
 1051 (4.5)  1153 (5.0) 0.87 (0.77 − 0.99)
Total 11503 (3.0) 13967 (3.7) 0.79 (0.77 − 0.81)
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Data on participants with missing baseline data included in totals.
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b) Excluding four trials that exclusively included participants with heart failure or on dialysis
Events (% p.a.)
χ1
2
=0.98
(p=0.3)
 ≤ 55 years
 2129 (2.7)  2680 (3.4) 0.75 (0.69 − 0.81)
 >55, ≤ 60 years
 1637 (2.5)  2018 (3.2) 0.78 (0.72 − 0.85)
 >60, ≤ 65 years
 2083 (2.7)  2549 (3.4) 0.79 (0.74 − 0.86)
 >65, ≤ 70 years
 2065 (2.9)  2666 (3.8) 0.74 (0.69 − 0.80)
 >70, ≤ 75 years
 1802 (3.7)  2134 (4.5) 0.80 (0.73 − 0.87)
 >75 years
  802 (4.1)   893 (4.7) 0.82 (0.70 − 0.95)
Total 10518 (2.9) 12940 (3.7) 0.77 (0.75 − 0.79)
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Figure 2: Effects on MAJOR VASCULAR EVENTS per mmol/L reduction in LDL cholesterol, 
subdivided by age at randomisation and particular trial populations
Events (% p.a.)
≤75  years
χ1
2
=14.51
(p=0.0001)
 >75 years
χ1
2
=3.37
(p=0.07)
All participants
χ1
2
=21.01
(p<0.0001)
 HF trials   304 (3.0)   308 (3.1) 0.96 (0.79 − 1.16)
 Dialysis trials   432 (7.9)   459 (8.5) 0.93 (0.78 − 1.11)
 Other trials  9716 (2.9) 12047 (3.6) 0.77 (0.74 − 0.80)
Subtotal 10452 (2.9) 12814 (3.7) 0.78 (0.76 − 0.80)
 HF trials   175 (4.8)   189 (5.1) 0.95 (0.75 − 1.22)
 Dialysis trials    74 (12.8)    71 (11.4) 1.10 (0.71 − 1.71)
 Other trials   802 (4.1)   893 (4.7) 0.82 (0.70 − 0.95)
Subtotal  1051 (4.5)  1153 (5.0) 0.87 (0.79 − 0.96)
 HF trials   479 (3.5)   497 (3.6) 0.95 (0.82 − 1.11)
 Dialysis trials   506 (8.3)   530 (8.8) 0.95 (0.81 − 1.12)
 Other trials 10518 (2.9) 12940 (3.7) 0.77 (0.75 − 0.80)
Total 11503 (3.0) 13967 (3.7) 0.79 (0.77 − 0.81)
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Figure 3: Effects on components of  MAJOR VASCULAR EVENTS per mmol/L reduction in LDL 
cholesterol in all studies, by age at randomisation
Events (% p.a.)
Major coronary event
χ1
2
=6.92
(p=0.009)
Coronary revascularisation
χ1
2
=0.33
(p=0.6)
Any stroke
χ1
2
=0.17
(p=0.7)
 ≤ 55 years
 920 (1.1) 1272 (1.5) 0.69 (0.62 − 0.77)
 >55, ≤ 60 years
 735 (1.1)  956 (1.4) 0.77 (0.68 − 0.87)
 >60, ≤ 65 years
 970 (1.2) 1294 (1.6) 0.74 (0.66 − 0.82)
 >65, ≤ 70 years 1066 (1.4) 1366 (1.8) 0.77 (0.69 − 0.85)
 >70, ≤ 75 years 1043 (1.9) 1225 (2.3) 0.81 (0.72 − 0.91)
 >75 years
 621 (2.6)  713 (3.0) 0.82 (0.70 − 0.96)
Total 5355 (1.4) 6826 (1.7) 0.76 (0.73 − 0.79)
 ≤ 55 years 1465 (1.7) 1865 (2.2) 0.75 (0.68 − 0.82)
 >55, ≤ 60 years 1013 (1.5) 1310 (1.9) 0.75 (0.67 − 0.83)
 >60, ≤ 65 years 1171 (1.4) 1397 (1.7) 0.81 (0.72 − 0.90)
 >65, ≤ 70 years
 999 (1.3) 1390 (1.8) 0.69 (0.62 − 0.77)
 >70, ≤ 75 years
 659 (1.2)  814 (1.5) 0.76 (0.65 − 0.89)
 >75 years
 210 (0.9)  209 (0.9) 1.02 (0.75 − 1.40)
 Total 5517 (1.4) 6985 (1.8) 0.75 (0.73 − 0.78)
 ≤ 55 years
 245 (0.3)  291 (0.3) 0.78 (0.62 − 0.98)
 >55, ≤ 60 years
 287 (0.4)  299 (0.4) 0.93 (0.75 − 1.14)
 >60, ≤ 65 years
 462 (0.6)  586 (0.7) 0.82 (0.70 − 0.96)
 >65, ≤ 70 years
 575 (0.7)  677 (0.9) 0.83 (0.72 − 0.96)
 >70, ≤ 75 years
 579 (1.1)  679 (1.3) 0.84 (0.72 − 0.98)
 >75 years
 336 (1.4)  366 (1.5) 0.89 (0.71 − 1.10)
 Total 2484 (0.6) 2898 (0.7) 0.84 (0.80 − 0.89)
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Figure 4: Effects on MAJOR VASCULAR EVENTS per mmol/L reduction in LDL cholesterol,
subdivided by age at randomisation and by prior vascular disease
Events (% p.a.)
Participants without vascular disease
χ1
2
=3.85
(p=0.05)
Participants with vascular disease
χ1
2
=1.42
(p=0.2)
 ≤ 55 years
 290 (0.8)   408 (1.2) 0.68 (0.56 − 0.83)
 >55, ≤ 60 years
 350 (1.0)   415 (1.2) 0.81 (0.67 − 0.99)
 >60, ≤ 65 years
 416 (1.1)   545 (1.5) 0.73 (0.61 − 0.87)
 >65, ≤ 70 years
 374 (1.2)   581 (1.8) 0.61 (0.51 − 0.73)
 >70, ≤ 75 years
 400 (2.1)   462 (2.4) 0.84 (0.70 − 1.01)
 >75 years
 295 (2.7)   308 (2.8) 0.92 (0.73 − 1.16)
Subtotal 2125 (1.3)  2719 (1.6) 0.75 (0.71 − 0.80)
 ≤ 55 years 1927 (4.0)  2370 (5.1) 0.77 (0.71 − 0.83)
 >55, ≤ 60 years 1391 (4.2)  1692 (5.2) 0.80 (0.73 − 0.88)
 >60, ≤ 65 years 1822 (4.4)  2178 (5.3) 0.81 (0.75 − 0.88)
 >65, ≤ 70 years 1889 (4.3)  2286 (5.5) 0.79 (0.73 − 0.86)
 >70, ≤ 75 years 1593 (4.8)  1877 (5.8) 0.80 (0.73 − 0.88)
 >75 years
 756 (6.0)   845 (6.8) 0.85 (0.73 − 0.98)
Subtotal 9378 (4.4) 11248 (5.4) 0.80 (0.77 − 0.82)
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Figure 5: Effects on VASCULAR DEATH per mmol/L reduction in LDL cholesterol, by age
at randomisation
a) All studies
Events (% p.a.)
χ1
2
=8.29
(p=0.004)
 ≤ 55 years
 407 (0.5)  527 (0.6) 0.74 (0.63 − 0.87)
 >55, ≤ 60 years
 457 (0.6)  502 (0.7) 0.94 (0.79 − 1.10)
 >60, ≤ 65 years
 820 (1.0)  974 (1.2) 0.83 (0.74 − 0.94)
 >65, ≤ 70 years 1136 (1.4) 1313 (1.7) 0.85 (0.77 − 0.94)
 >70, ≤ 75 years 1202 (2.2) 1258 (2.3) 0.94 (0.85 − 1.04)
 >75 years
 930 (3.7)  976 (4.0) 0.95 (0.83 − 1.07)
Total 4952 (1.2) 5550 (1.4) 0.88 (0.85 − 0.91)
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Data on participants with missing baseline data included in totals.
LDL−C lowering
worse
LDL−C lowering
better
b) Excluding four trials that exclusively included participants with heart failure or on dialysis
Events (% p.a.)
χ1
2
=1.61
(p=0.2)
 ≤ 55 years
 326 (0.4)  428 (0.5) 0.73 (0.61 − 0.88)
 >55, ≤ 60 years
 355 (0.5)  396 (0.6) 0.92 (0.77 − 1.11)
 >60, ≤ 65 years
 611 (0.8)  740 (0.9) 0.81 (0.71 − 0.93)
 >65, ≤ 70 years
 844 (1.1) 1018 (1.4) 0.82 (0.73 − 0.92)
 >70, ≤ 75 years
 850 (1.6)  947 (1.8) 0.87 (0.77 − 0.99)
 >75 years
 435 (2.1)  457 (2.3) 0.86 (0.69 − 1.08)
Total 3421 (0.9) 3986 (1.0) 0.84 (0.80 − 0.88)
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